1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,750 | 6,050 | 10:51 | |
| 5,850 | 6,000 | 09:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11.25 | Goldman Sachs initiates Keymed Biosciences stock with Buy rating | 1 | Investing.com | ||
| 03.11.25 | Goldman Sachs: Kaufempfehlung für Keymed Biosciences zum Start der Analyse | - | Investing.com Deutsch | ||
| 25.09.25 | KEYMED BIO-B (02162): 2025 INTERIM REPORT | - | HKEx | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.08.25 | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | 296 | PR Newswire | CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially... ► Artikel lesen | |
| 26.08.25 | KEYMED BIO-B (02162): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025; AND RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY ... | 1 | HKEx | ||
| 13.06.25 | Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine | 831 | PR Newswire | CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases... ► Artikel lesen | |
| 27.04.25 | Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt | 174 | PR Newswire | CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein... ► Artikel lesen | |
| 25.04.25 | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | 437 | PR Newswire | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed... ► Artikel lesen | |
| 07.04.25 | Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht | 352 | PR Newswire | CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische... ► Artikel lesen | |
| 05.04.25 | Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine | 806 | PR Newswire | CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published... ► Artikel lesen | |
| 26.03.25 | Keymed Biosciences Announces Annual Results of 2024 | 237 | PR Newswire | CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 328,93 | 0,00 % | Praxis Precision Medicines Q4 2025 Earnings Preview | ||
| VERA THERAPEUTICS | 44,070 | 0,00 % | Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) | ||
| IMMUNOVANT | 26,650 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 22,410 | 0,00 % | Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating | ||
| SENSEI BIOTHERAPEUTICS | 26,010 | 0,00 % | Sensei Biotherapeutics Stock Soars 230% After Faeth Deal | ||
| AVIDITY BIOSCIENCES | 72,83 | -0,04 % | Avidity: Vielversprechende Studienergebnisse für Medikament gegen myotone Dystrophie | ||
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Aktien New York Ausblick: Gewinne erwartet - Nvidia führt Tech-Riesen an | NEW YORK (dpa-AFX) - Nach ihrem verhaltenen Auftakt in die verkürzte Börsenwoche dürften die US-Aktienmärkte am Mittwoch einen Erholungsversuch starten. Bevor am Abend das Sitzungsprotokoll der US-Notenbank... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,450 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,410 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,200 | +0,48 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,350 | 0,00 % | Cogent Biosciences, Inc. - 10-K, Annual Report | ||
| SUMMIT THERAPEUTICS | 15,880 | 0,00 % | Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough | ||
| STRUCTURE THERAPEUTICS | 68,26 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,150 | 0,00 % | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen | |
| DISC MEDICINE | 64,49 | 0,00 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen |
Das Unternehmen KEYMED BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,750 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.